EULAR Congress 2026: key results and trends

Obexelimab reduced the risk of flare by 56% versus placebo (HR 0.443; 95% CI 0.277–0.711; p=0.0005).

The risk of requiring escape or rescue treatment was reduced by 50% for both secukinumab doses compared to placebo (hazard ratios of 0.5; P<0.001 for SEC-300 and P<0.01 for SEC-150).

In the patients with autoimmune ILDs, both doses of nerandomilast had a nominally significant effect on the risk of death (HR vs placebo: 0.40 [95% CI: 0.17, 0.94] for 9 mg bid and 0.28 [95% CI: 0.11, 0.69] for 18 mg bid).

Mepolizumab increased accrued duration in remission versus placebo (odds ratio (OR) [95% CI], 5.47 [1.45, 20.53], p=0.012), with 42% of patients treated with mepolizumab spending 12 or more weeks in remission compared with 4% with placebo.

Improvements in ACR70 (34.4% vs 7.5%), DAS28(CRP)<2.6 (48.8% vs 12.6%), CDAI≤10 (61.4% vs 22.4%), and SDAI≤11 (63.7% vs 23.8%) remained significant (all p<0.0001).

Compared to placebo, a statistically significant decrease in ESSDAI score from baseline at Week 24 was observed in Telitacicept 160 mg (LS Mean change: -4.4 vs -0.6, p<0.0001) and Telitacicept 80 mg (LS Mean change: -3.0 vs -0.6, p<0.0001).

Thirty-two subjects (4.5%) experienced serious TEAEs (5.4% in BAT2506 group, 4.3% in RP group, and 3.0% in RP-BAT2506 group).

Brepocitinib 30 mg was also associated with increased achievement of CDASI-A response, with nominal statistical significance achieved at weeks 4, 8, and 12, and high rates of CDASI-A response with brepocitinib 30 mg (49.4% at Week 8; 56.8% at Week 12).

The overall incidence of treatment-emergent adverse events (TEAEs) was similar between the HR091506 and febuxostat groups (90.5% vs 90.0%), as was the incidence of treatment-related TEAEs (65.6% vs 70.1%).

For the primary endpoint of ACR50 at Week 16, BKZ was superior to RZB, with response in 49.1% vs 38.4% of pts (p=0.0078).

The ASAS20 response also significantly favored gecacitinib (69.2% vs. 21.2%, p<0.0001).

At W24, GUS-treated participants had -43.0% (Q4W) and -35.8% (Q8W) change from baseline (improvement) in mNAPSI compared with 16.1% (PBO), and greater response rates for achieving mNAPSI 50, mNAPSI 75, and mNAPSI 100 among GUS-treated participants.